Skip to main content

VistaGen Therapeutics, Inc. (VTGN)

NASDAQ: VTGN · IEX Real-Time Price · USD
1.67
-0.13 (-7.22%)
At close: Dec 3, 2021 4:00 PM
1.68
0.01 (0.60%)
After-hours:Dec 3, 2021 7:31 PM EST
Market Cap359.46M
Revenue (ttm)1.47M
Net Income (ttm)-56.49M
Shares Out215.25M
EPS (ttm)-0.37
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,228,263
Open1.80
Previous Close1.80
Day's Range1.66 - 1.81
52-Week Range0.72 - 3.55
Beta0.86
AnalystsStrong Buy
Price Target7.33 (+338.9%)
Earnings DateNov 10, 2021

About VTGN

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment diso...

IndustryBiotechnology
Founded1998
Employees26
Stock ExchangeNASDAQ
Ticker SymbolVTGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for VTGN stock is "Strong Buy." The 12-month stock price forecast is 7.33, which is an increase of 338.92% from the latest price.

Price Target
$7.33
(338.92% upside)
Analyst Consensus: Strong Buy

News

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Tops Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -40.00% and 9.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the...

3 weeks ago - Zacks Investment Research

VistaGen Therapeutics Reports Fiscal Year 2022 Second Quarter Financial Results and Provides Corporate Update

PALISADE Phase 3 clinical trials of PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan

3 weeks ago - GlobeNewsWire

Will VistaGen Therapeutics, Inc. (VTGN) Report Negative Q2 Earnings? What You Should Know

VistaGen Therapeutics, Inc. (VTGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago - Zacks Investment Research

VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder

Study Launches Phase 2A Clinical Program Designed to Explore PH94B's Potential in Multiple Additional Anxiety Disorders

1 month ago - GlobeNewsWire

VistaGen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94B's Potential Anti-Anxiety Acti...

Preclinical study of intranasal radiolabeled PH94B in laboratory rats further differentiates PH94B's mechanism of action from benzodiazepines Preclinical study of intranasal radiolabeled PH94B in labora...

1 month ago - GlobeNewsWire

VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation ...

PALISADE Phase 3 Program focused on PH94B's potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorder PALISADE Phase 3 Program focused on PH94B's potential as a rapid...

2 months ago - GlobeNewsWire

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 20.00% and -4.58%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Recap: VistaGen Therapeutics Q1 Earnings

Shares of VistaGen Therapeutics (NASDAQ:VTGN) fell 1.5% in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 42.86% over the past year to ($0.04), ...

3 months ago - Benzinga

VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update

PALISADE Phase 3 Program to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan

3 months ago - GlobeNewsWire

VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential ...

4 months ago - GlobeNewsWire

VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021

SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential ...

4 months ago - GlobeNewsWire

VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors

Ms. Rotunno brings extensive healthcare industry expertise as a leader and strategist as VistaGen advances late-stage development of its product candidates for anxiety and depression disorders Ms. Rotun...

4 months ago - GlobeNewsWire

Are These 8 Penny Stocks to Watch on Your List Right Now?

Making a penny stocks watchlist for 2021? Check these 8 out The post Are These 8 Penny Stocks to Watch on Your List Right Now?

5 months ago - PennyStocks

Why VistaGen Therapeutics Stock Jumped Today

Investors liked the drugmaker's corporate update.

5 months ago - The Motley Fool

VistaGen Therapeutics: Q4 Earnings Insights

Shares of VistaGen Therapeutics (NASDAQ:VTGN) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 328.57% over the past year to ($0.30...

5 months ago - Benzinga

VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update

PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD)

5 months ago - GlobeNewsWire

8 Penny Stocks to Watch Right Now As June Comes to an End

Which penny stocks are investors watching as June comes to an end? The post 8 Penny Stocks to Watch Right Now As June Comes to an End appeared first on Penny Stocks to Buy, Picks, News and Information |...

5 months ago - PennyStocks

VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference...

SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the pot...

5 months ago - GlobeNewsWire

Sage Stock Declines on Late-Stage Depression Study Data

Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.

Other symbols:BIIBNERVSAGE
5 months ago - Zacks Investment Research

VistaGen Therapeutics Set to Join the Russell 2000® Index

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of me...

5 months ago - GlobeNewsWire

7 A-Rated Biotech Stocks to Buy Now

Investors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios. The post 7 A-Rated Biotech Stocks to Buy Now appeared first on Inves...

Other symbols:BNGOBNTXCDMOMRNA
5 months ago - InvestorPlace

5 Buy-Rated Stocks Trading Below $10 With Outstanding Upside Potential

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other symbols:MBIOIPWWDH
5 months ago - 24/7 Wall Street

VistaGen Kick Starts Late-Stage Social Anxiety Disorder Study with PH94B

VistaGen Therapeutics Inc (NASDAQ: VTGN) has initiated its PALISADE Phase 3 study to evaluate PH94B for the acute treatment of Social Anxiety Disorder (SAD). PH94B is an odorless, rapid-onset, investiga...

6 months ago - Benzinga

5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now

Analysts say these are penny stocks to buy right now & have bullish targets to back it up. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now appeared first on Penny Stocks to...

Other symbols:ITRMMRKRSESNTELL
6 months ago - PennyStocks